Cargando…
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. Centralization of rare cancer in dedicated centers is recommended to ensure expertise, multidisciplinarity and access to innovation. In Italy, expert centers for MPM have not been identified in all regions. We a...
Autores principales: | Trama, Annalisa, Proto, Claudia, Signorelli, Diego, Garassino, Marina C., Lo Russo, Giuseppe, Ganzinelli, Monica, Prelaj, Arsela, Mensi, Carolina, Gangemi, Manuela, Gennaro, Valerio, Chellini, Elisabetta, Caldarella, Adele, Angelillo, Italo F., Ascoli, Valeria, Pascucci, Cristiana, Tagliabue, Giovanna, Cusimano, Rosanna, Bella, Francesca, Falcini, Fabio, Merler, Enzo, Masanotti, Giuseppe, Ziino, Antonio, Michiara, Maria, Gola, Gemma, Storchi, Cinzia, Mangone, Lucia, Vitale, Maria F., Cirilli, Claudia, Tumino, Rosario, Scuderi, Tiziana, Fanetti, Anna C., Piffer, Silvano, Tiseo, Marcello, Gatta, Gemma, Botta, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262944/ https://www.ncbi.nlm.nih.gov/pubmed/32364316 http://dx.doi.org/10.1111/1759-7714.13456 |
Ejemplares similares
-
SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020) -
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021) -
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022) -
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022) -
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)